New combo approach shows promise for tough-to-treat liver cancer
NCT ID NCT06881446
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study looked at adding a procedure called TACE (which blocks the tumor's blood supply) to a mix of immunotherapy and targeted drugs for people with advanced liver cancer that has spread into major blood vessels. Over 2,600 participants were included. The goal was to see if the triple combination helped people live longer or kept the cancer from growing longer than the drug combination alone. The results help doctors understand the best first treatment for this challenging condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.